215 related articles for article (PubMed ID: 34217823)
1. Innovative lipoplexes formulations with enhanced siRNA efficacy for cancer treatment: Where are we now?
Berger M; Lechanteur A; Evrard B; Piel G
Int J Pharm; 2021 Aug; 605():120851. PubMed ID: 34217823
[TBL] [Abstract][Full Text] [Related]
2. Delivery Strategies for mRNA Vaccines.
Ramachandran S; Satapathy SR; Dutta T
Pharmaceut Med; 2022 Feb; 36(1):11-20. PubMed ID: 35094366
[TBL] [Abstract][Full Text] [Related]
3. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
4. Effect of the nanoformulation of siRNA-lipid assemblies on their cellular uptake and immune stimulation.
Kubota K; Onishi K; Sawaki K; Li T; Mitsuoka K; Sato T; Takeoka S
Int J Nanomedicine; 2017; 12():5121-5133. PubMed ID: 28790820
[TBL] [Abstract][Full Text] [Related]
5. Cuboplexes: Topologically Active siRNA Delivery.
Kim H; Leal C
ACS Nano; 2015 Oct; 9(10):10214-26. PubMed ID: 26390340
[TBL] [Abstract][Full Text] [Related]
6. Zwitterionic poly(carboxybetaine)-based cationic liposomes for effective delivery of small interfering RNA therapeutics without accelerated blood clearance phenomenon.
Li Y; Liu R; Shi Y; Zhang Z; Zhang X
Theranostics; 2015; 5(6):583-96. PubMed ID: 25825598
[TBL] [Abstract][Full Text] [Related]
7. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
[TBL] [Abstract][Full Text] [Related]
8. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing.
Cardoso AL; Simões S; de Almeida LP; Pelisek J; Culmsee C; Wagner E; Pedroso de Lima MC
J Gene Med; 2007 Mar; 9(3):170-83. PubMed ID: 17351968
[TBL] [Abstract][Full Text] [Related]
9. Control of cell penetration enhancer shielding and endosomal escape-kinetics crucial for efficient and biocompatible siRNA delivery.
Malfanti A; Sami H; Balasso A; Marostica G; Arpac B; Mastrotto F; Mantovani G; Cola E; Anton M; Caliceti P; Ogris M; Salmaso S
J Control Release; 2023 Nov; 363():101-113. PubMed ID: 37722420
[TBL] [Abstract][Full Text] [Related]
10. Functional Peptide-Modified Liposomes for siRNA Delivery to Rat Retinal Pigment Epithelium Cells: Effect of Peptide Sequences.
Nishida S; Takashima Y; Endo K; Ishihara H
Biol Pharm Bull; 2023; 46(10):1468-1478. PubMed ID: 37779049
[TBL] [Abstract][Full Text] [Related]
11. Hydrophobic scaffolds of pH-sensitive cationic lipids contribute to miscibility with phospholipids and improve the efficiency of delivering short interfering RNA by small-sized lipid nanoparticles.
Sato Y; Okabe N; Note Y; Hashiba K; Maeki M; Tokeshi M; Harashima H
Acta Biomater; 2020 Jan; 102():341-350. PubMed ID: 31733331
[TBL] [Abstract][Full Text] [Related]
12. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo.
Sato Y; Hashiba K; Sasaki K; Maeki M; Tokeshi M; Harashima H
J Control Release; 2019 Feb; 295():140-152. PubMed ID: 30610950
[TBL] [Abstract][Full Text] [Related]
13. Effects of cationic lipids in cationic liposomes and disaccharides in the freeze-drying of siRNA lipoplexes on gene silencing in cells by reverse transfection.
Hattori Y; Hu S; Onishi H
J Liposome Res; 2020 Sep; 30(3):235-245. PubMed ID: 31185779
[TBL] [Abstract][Full Text] [Related]
14. Bridging small interfering RNA with giant therapeutic outcomes using nanometric liposomes.
Singh Y; Tomar S; Khan S; Meher JG; Pawar VK; Raval K; Sharma K; Singh PK; Chaurasia M; Surendar Reddy B; Chourasia MK
J Control Release; 2015 Dec; 220(Pt A):368-387. PubMed ID: 26528900
[TBL] [Abstract][Full Text] [Related]
15. Enhanced endosomal/lysosomal escape by distearoyl phosphoethanolamine-polycarboxybetaine lipid for systemic delivery of siRNA.
Li Y; Cheng Q; Jiang Q; Huang Y; Liu H; Zhao Y; Cao W; Ma G; Dai F; Liang X; Liang Z; Zhang X
J Control Release; 2014 Feb; 176():104-14. PubMed ID: 24365128
[TBL] [Abstract][Full Text] [Related]
16. Environment-Responsive Lipid/siRNA Nanoparticles for Cancer Therapy.
Lu ZR; Laney VEA; Hall R; Ayat N
Adv Healthc Mater; 2021 Mar; 10(5):e2001294. PubMed ID: 33615743
[TBL] [Abstract][Full Text] [Related]
17. Tunable rigidity of PLGA shell-lipid core nanoparticles for enhanced pulmonary siRNA delivery in 2D and 3D lung cancer cell models.
Wang H; Yuan Y; Qin L; Yue M; Xue J; Cui Z; Zhan X; Gai J; Zhang X; Guan J; Mao S
J Control Release; 2024 Feb; 366():746-760. PubMed ID: 38237688
[TBL] [Abstract][Full Text] [Related]
18. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
[TBL] [Abstract][Full Text] [Related]
19. Cationic lipid nanoparticle production by microfluidization for siRNA delivery.
Liu X; Bahloul B; Lai Kuen R; Andrieux K; Roques C; Scherman D
Int J Pharm; 2021 Aug; 605():120772. PubMed ID: 34098051
[TBL] [Abstract][Full Text] [Related]
20. Characterization of long-circulating cationic nanoparticle formulations consisting of a two-stage PEGylation step for the delivery of siRNA in a breast cancer tumor model.
Ho EA; Osooly M; Strutt D; Masin D; Yang Y; Yan H; Bally M
J Pharm Sci; 2013 Jan; 102(1):227-36. PubMed ID: 23132529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
